BTK inhibitor therapy for CLL/SLL in China

This study compares a fixed-cycle treatment with a BTK inhibitor (a type of targeted therapy) to see which works better for CLL/SLL. It is for people who need treatment and have not had standard therapy before.

This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.

This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.

This study looks at how well BTK inhibitors work in people with chronic lymphocytic leukemia (CLL) in real-world settings. It includes both new patients and those who have had treatment before.

This study follows patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—blood cancers—who have been taking a type of targeted drug called a BTK inhibitor for at least 2 years. Researchers want to understand what happens to these patients' cancer and health after they stop taking this medication.

This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.